Morgan Stanley Praxis Precision Medicines, Inc. Transaction History

Morgan Stanley

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	BUY	$0.87 - $1.71 $41,078 - $80,741	47,217 Added 19.43%	290,213 $496,000
Q2 2023 Aug 14, 2023	SELL	$0.83 - $1.18 $485,996 - $690,934	-585,538 Reduced 70.67%	242,996 $279,000
Q1 2023 May 15, 2023	BUY	$0.8 - $4.98 $517,181 - $3.22 Million	646,477 Added 355.1%	828,534 $671,000
Q4 2022 Feb 14, 2023	SELL	$1.88 - $36.45 $174,494 - $3.38 Million	-92,816 Reduced 33.77%	182,057 $433,000
Q3 2022 Nov 14, 2022	SELL	$2.5 - $37.95 $630,875 - $9.58 Million	-252,350 Reduced 47.86%	274,873 $624,000
Q2 2022 Oct 27, 2022	BUY	$1.75 - $11.34 $796,468 - $5.16 Million	455,125 Added 631.26%	527,223 $1.29 Million
Q2 2022 Aug 15, 2022	BUY	$1.75 - $11.34 $796,468 - $5.16 Million	455,125 Added 631.26%	527,223 $1.29 Million
Q1 2022 Oct 27, 2022	SELL	$10.21 - $20.29 $4.65 Million - $9.23 Million	-455,125 Reduced 86.32%	72,098 $737,000
Q1 2022 May 13, 2022	BUY	$10.21 - $20.29 $528,949 - $1.05 Million	51,807 Added 255.32%	72,098 $737,000
Q4 2021 Feb 14, 2022	BUY	$16.76 - $22.99 $97,325 - $133,502	5,807 Added 40.09%	20,291 $400,000
Q3 2021 Nov 15, 2021	BUY	$13.15 - $22.56 $190,464 - $326,759	14,484 New	14,484 $267,000

75K

Ticker PRAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,576,100
Market Cap $2.62B
Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of ...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.